APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multiple Sclerosis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Multiple Sclerosis Drugs Market Outlook and Growth Opportunities 2026

20 December 2025194 pages

Choose your research edition.

Industry ResearchMultiple Sclerosis Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiple Sclerosis Drugs Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Multiple Sclerosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiple Sclerosis Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiple Sclerosis Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Multiple Sclerosis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Multiple Sclerosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multiple Sclerosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multiple Sclerosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Multiple Sclerosis Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Multiple Sclerosis Drugs market include ACORDA, Biogen, Mallinckrodt, Bayer, Merck KGaA, Novartis, Sanofi and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Multiple Sclerosis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multiple Sclerosis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multiple Sclerosis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Multiple Sclerosis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Multiple Sclerosis Drugs Segment by Company

ACORDA

Biogen

Mallinckrodt

Bayer

Merck KGaA

Novartis

Sanofi

Teva

Multiple Sclerosis Drugs Segment by Type

Injectable Medications

Oral Medications

Others

Multiple Sclerosis Drugs Segment by Application

Adults

Children

Multiple Sclerosis Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Multiple Sclerosis Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Multiple Sclerosis Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Multiple Sclerosis Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Multiple Sclerosis Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Sclerosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiple Sclerosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Sclerosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Multiple Sclerosis Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Multiple Sclerosis Drugs industry.

Chapter 3: Detailed analysis of Multiple Sclerosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Multiple Sclerosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Multiple Sclerosis Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Multiple Sclerosis Drugs Industry Trends Table 2. Multiple Sclerosis Drugs Industry Drivers Table 3. Multiple Sclerosis Drugs Industry Opportunities and Challenges Table 4. Multiple Sclerosis Drugs Industry Restraints Table 5. Global Multiple Sclerosis Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Multiple Sclerosis Drugs Revenue Share by Company (2021-2026) Table 7. Global Multiple Sclerosis Drugs Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Multiple Sclerosis Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Multiple Sclerosis Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Multiple Sclerosis Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Multiple Sclerosis Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Multiple Sclerosis Drugs Company, Product Type & Application Table 13. Global Multiple Sclerosis Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Multiple Sclerosis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Injectable Medications Table 18. Significant Companies of Oral Medications Table 19. Significant Companies of Others Table 20. Global Multiple Sclerosis Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 21. Global Multiple Sclerosis Drugs Sales Volume by Type (2021-2026) & (W Units) Table 22. Global Multiple Sclerosis Drugs Sales Volume by Type (2027-2032) & (W Units) Table 23. Global Multiple Sclerosis Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Multiple Sclerosis Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Multiple Sclerosis Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Multiple Sclerosis Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Multiple Sclerosis Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Multiple Sclerosis Drugs Sales Value Share by Type (2021-2026) Table 29. Global Multiple Sclerosis Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Adults Table 31. Significant Companies of Children Table 32. Global Multiple Sclerosis Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 33. Global Multiple Sclerosis Drugs Sales Volume by Application (2021-2026) & (W Units) Table 34. Global Multiple Sclerosis Drugs Sales Volume by Application (2027-2032) & (W Units) Table 35. Global Multiple Sclerosis Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Multiple Sclerosis Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Multiple Sclerosis Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Multiple Sclerosis Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Multiple Sclerosis Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Multiple Sclerosis Drugs Sales Value Share by Application (2021-2026) Table 41. Global Multiple Sclerosis Drugs Sales Value Share by Application (2027-2032) Table 42. Global Multiple Sclerosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 43. Global Multiple Sclerosis Drugs Sales by Region (2021-2026) & (W Units) Table 44. Global Multiple Sclerosis Drugs Sales Market Share by Region (2021-2026) Table 45. Global Multiple Sclerosis Drugs Sales by Region (2027-2032) & (W Units) Table 46. Global Multiple Sclerosis Drugs Sales Market Share by Region (2027-2032) Table 47. Global Multiple Sclerosis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Multiple Sclerosis Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Multiple Sclerosis Drugs Sales Value Share by Region (2021-2026) Table 50. Global Multiple Sclerosis Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Multiple Sclerosis Drugs Sales Value Share by Region (2027-2032) Table 52. Global Multiple Sclerosis Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Multiple Sclerosis Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Multiple Sclerosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Global Multiple Sclerosis Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Multiple Sclerosis Drugs Sales by Country (2021-2026) & (W Units) Table 57. Global Multiple Sclerosis Drugs Sales Market Share by Country (2021-2026) Table 58. Global Multiple Sclerosis Drugs Sales by Country (2027-2032) & (W Units) Table 59. Global Multiple Sclerosis Drugs Sales Market Share by Country (2027-2032) Table 60. Global Multiple Sclerosis Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Multiple Sclerosis Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Multiple Sclerosis Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Multiple Sclerosis Drugs Sales Value Market Share by Country (2027-2032) Table 64. ACORDA Company Information Table 65. ACORDA Business Overview Table 66. ACORDA Multiple Sclerosis Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. ACORDA Multiple Sclerosis Drugs Product Portfolio Table 68. ACORDA Recent Development Table 69. Biogen Company Information Table 70. Biogen Business Overview Table 71. Biogen Multiple Sclerosis Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Biogen Multiple Sclerosis Drugs Product Portfolio Table 73. Biogen Recent Development Table 74. Mallinckrodt Company Information Table 75. Mallinckrodt Business Overview Table 76. Mallinckrodt Multiple Sclerosis Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Mallinckrodt Multiple Sclerosis Drugs Product Portfolio Table 78. Mallinckrodt Recent Development Table 79. Bayer Company Information Table 80. Bayer Business Overview Table 81. Bayer Multiple Sclerosis Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Bayer Multiple Sclerosis Drugs Product Portfolio Table 83. Bayer Recent Development Table 84. Merck KGaA Company Information Table 85. Merck KGaA Business Overview Table 86. Merck KGaA Multiple Sclerosis Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Merck KGaA Multiple Sclerosis Drugs Product Portfolio Table 88. Merck KGaA Recent Development Table 89. Novartis Company Information Table 90. Novartis Business Overview Table 91. Novartis Multiple Sclerosis Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Novartis Multiple Sclerosis Drugs Product Portfolio Table 93. Novartis Recent Development Table 94. Sanofi Company Information Table 95. Sanofi Business Overview Table 96. Sanofi Multiple Sclerosis Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Sanofi Multiple Sclerosis Drugs Product Portfolio Table 98. Sanofi Recent Development Table 99. Teva Company Information Table 100. Teva Business Overview Table 101. Teva Multiple Sclerosis Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Teva Multiple Sclerosis Drugs Product Portfolio Table 103. Teva Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Multiple Sclerosis Drugs Distributors List Table 107. Multiple Sclerosis Drugs Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Multiple Sclerosis Drugs Product Image Figure 2. Global Multiple Sclerosis Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multiple Sclerosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Multiple Sclerosis Drugs Sales (2021-2032) & (W Units) Figure 5. Global Multiple Sclerosis Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Multiple Sclerosis Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Injectable Medications Image Figure 10. Oral Medications Image Figure 11. Others Image Figure 12. Global Multiple Sclerosis Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 13. Global Multiple Sclerosis Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Multiple Sclerosis Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Multiple Sclerosis Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Multiple Sclerosis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Multiple Sclerosis Drugs Sales Value Share by Type (2021-2032) Figure 18. Adults Image Figure 19. Children Image Figure 20. Global Multiple Sclerosis Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 21. Global Multiple Sclerosis Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Multiple Sclerosis Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Multiple Sclerosis Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Multiple Sclerosis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Multiple Sclerosis Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Multiple Sclerosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 27. Global Multiple Sclerosis Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Multiple Sclerosis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Multiple Sclerosis Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Multiple Sclerosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Multiple Sclerosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Multiple Sclerosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Multiple Sclerosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Multiple Sclerosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Multiple Sclerosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Multiple Sclerosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Multiple Sclerosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Multiple Sclerosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Multiple Sclerosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Multiple Sclerosis Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Multiple Sclerosis Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Injectable Medications
  • Oral Medications
  • Others
Applications
  • Adults
  • Children
Companies covered
  • ACORDA
  • Biogen
  • Mallinckrodt
  • Bayer
  • Merck KGaA
  • Novartis
  • Sanofi
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Multiple Sclerosis Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Multiple Sclerosis Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Multiple Sclerosis Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Multiple Sclerosis Drugs Market Dynamics
  1. 2.1 Multiple Sclerosis Drugs Industry Trends
  2. 2.2 Multiple Sclerosis Drugs Industry Drivers
  3. 2.3 Multiple Sclerosis Drugs Industry Opportunities and Challenges
  4. 2.4 Multiple Sclerosis Drugs Industry Restraints
3 Multiple Sclerosis Drugs Market by Company
  1. 3.1 Global Multiple Sclerosis Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Multiple Sclerosis Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Multiple Sclerosis Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Multiple Sclerosis Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Multiple Sclerosis Drugs Company Ranking (2024-2026)
  6. 3.6 Global Multiple Sclerosis Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Multiple Sclerosis Drugs Company Product Type and Application
  8. 3.8 Global Multiple Sclerosis Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Multiple Sclerosis Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Multiple Sclerosis Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Multiple Sclerosis Drugs Market by Type
  1. 4.1 Multiple Sclerosis Drugs Type Introduction
  2. 4.1.1 Injectable Medications
  3. 4.1.2 Oral Medications
  4. 4.1.3 Others
  5. 4.2 Global Multiple Sclerosis Drugs Sales Volume by Type
  6. 4.2.1 Global Multiple Sclerosis Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Multiple Sclerosis Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Multiple Sclerosis Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Multiple Sclerosis Drugs Sales Value by Type
  10. 4.3.1 Global Multiple Sclerosis Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Multiple Sclerosis Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Multiple Sclerosis Drugs Sales Value Share by Type (2021-2032)
5 Multiple Sclerosis Drugs Market by Application
  1. 5.1 Multiple Sclerosis Drugs Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Children
  4. 5.2 Global Multiple Sclerosis Drugs Sales Volume by Application
  5. 5.2.1 Global Multiple Sclerosis Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Multiple Sclerosis Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Multiple Sclerosis Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Multiple Sclerosis Drugs Sales Value by Application
  9. 5.3.1 Global Multiple Sclerosis Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Multiple Sclerosis Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Multiple Sclerosis Drugs Sales Value Share by Application (2021-2032)
6 Multiple Sclerosis Drugs Regional Sales and Value Analysis
  1. 6.1 Global Multiple Sclerosis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multiple Sclerosis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Multiple Sclerosis Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Multiple Sclerosis Drugs Sales by Region (2027-2032)
  5. 6.3 Global Multiple Sclerosis Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Multiple Sclerosis Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Multiple Sclerosis Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Multiple Sclerosis Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Multiple Sclerosis Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Multiple Sclerosis Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Multiple Sclerosis Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Multiple Sclerosis Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Multiple Sclerosis Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Multiple Sclerosis Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Multiple Sclerosis Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Multiple Sclerosis Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Multiple Sclerosis Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Multiple Sclerosis Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Multiple Sclerosis Drugs Sales Value Share by Country, 2025 VS 2032
7 Multiple Sclerosis Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Multiple Sclerosis Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Multiple Sclerosis Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Multiple Sclerosis Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Multiple Sclerosis Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Multiple Sclerosis Drugs Sales by Country (2027-2032)
  6. 7.4 Global Multiple Sclerosis Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Multiple Sclerosis Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Multiple Sclerosis Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Multiple Sclerosis Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Multiple Sclerosis Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Multiple Sclerosis Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ACORDA
  2. 8.1.1 ACORDA Company Information
  3. 8.1.2 ACORDA Business Overview
  4. 8.1.3 ACORDA Multiple Sclerosis Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 ACORDA Multiple Sclerosis Drugs Product Portfolio
  6. 8.1.5 ACORDA Recent Developments
  7. 8.2 Biogen
  8. 8.2.1 Biogen Company Information
  9. 8.2.2 Biogen Business Overview
  10. 8.2.3 Biogen Multiple Sclerosis Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Biogen Multiple Sclerosis Drugs Product Portfolio
  12. 8.2.5 Biogen Recent Developments
  13. 8.3 Mallinckrodt
  14. 8.3.1 Mallinckrodt Company Information
  15. 8.3.2 Mallinckrodt Business Overview
  16. 8.3.3 Mallinckrodt Multiple Sclerosis Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mallinckrodt Multiple Sclerosis Drugs Product Portfolio
  18. 8.3.5 Mallinckrodt Recent Developments
  19. 8.4 Bayer
  20. 8.4.1 Bayer Company Information
  21. 8.4.2 Bayer Business Overview
  22. 8.4.3 Bayer Multiple Sclerosis Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bayer Multiple Sclerosis Drugs Product Portfolio
  24. 8.4.5 Bayer Recent Developments
  25. 8.5 Merck KGaA
  26. 8.5.1 Merck KGaA Company Information
  27. 8.5.2 Merck KGaA Business Overview
  28. 8.5.3 Merck KGaA Multiple Sclerosis Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck KGaA Multiple Sclerosis Drugs Product Portfolio
  30. 8.5.5 Merck KGaA Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Multiple Sclerosis Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Multiple Sclerosis Drugs Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Sanofi
  38. 8.7.1 Sanofi Company Information
  39. 8.7.2 Sanofi Business Overview
  40. 8.7.3 Sanofi Multiple Sclerosis Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi Multiple Sclerosis Drugs Product Portfolio
  42. 8.7.5 Sanofi Recent Developments
  43. 8.8 Teva
  44. 8.8.1 Teva Company Information
  45. 8.8.2 Teva Business Overview
  46. 8.8.3 Teva Multiple Sclerosis Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Teva Multiple Sclerosis Drugs Product Portfolio
  48. 8.8.5 Teva Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Multiple Sclerosis Drugs Value Chain Analysis
  2. 9.1.1 Multiple Sclerosis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Multiple Sclerosis Drugs Sales Mode & Process
  6. 9.2 Multiple Sclerosis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Multiple Sclerosis Drugs Distributors
  9. 9.2.3 Multiple Sclerosis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst